Serum Institute of India has commenced the construction of a new large scale cGMP production facility to manufacture CRM197, a non-toxic mutant of diphtheria toxin, for Phenex's Reagent Proteins division. The new facility, which will be able to produce 50kg/year of CRM197 using Pfenex's pseudomonas flourescens expression technology, is due to open in 2014.
GEN
Monday, 21 January 2013
Serum to add diphtheria toxin plant
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment